BN29553
Phase 3
Completed
- Conditions
- Alzheimer's disease(AD)
- Registration Number
- JPRN-jRCT2080223539
- Lead Sponsor
- CHUGAI PHARMACEUTICAL CO.,LTD.
- Brief Summary
Crenezumab did not demonstrate evidence of clinically meaningful effects the primary endpoint and secondary endpoints. Crenezumab was safety and well-tolerated in patients with prodromal to mild AD. The steady-state mean trough concentrations of crenezumab were maintained throughout the treatment period.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 806
Inclusion Criteria
Meet NIA-AA core clinical criteria for probable AD dementia or prodromal AD
-Having mild symptomatology, as defined by a screening MMSE score of 22 points and higher, and CDR-GS of 0.5 or 1.0
etc.
Exclusion Criteria
-Any evidence of a condition other than AD that may affect cognition
-Meet the exclusion criteria of MRI at screening
etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety<br>efficacy<br>Observation/Examination
- Secondary Outcome Measures
Name Time Method pharmacokinetics<br>pharmacodynamics<br>Examination